Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global acromegaly market was valued at US$ 1.56 billion in 2022 and is expected to register a revenue CAGR of 7.7% to reach US$ 3.04 billion by 2031. 

Acromegaly Market Fundamentals 

Acromegaly is a slowly progressive, acquired disorder that affects adults. It arises when the pituitary gland produces excessive growth hormone. Pituitary hormones regulate a wide range of bodily functions, including growth. Acromegaly is usually a result of the development of a benign tumor (adenoma) that arises from the pituitary gland. Acromegaly symptoms involve abnormal enlargement of the bones in the hands, arms, feet, legs, and head. The most visible bony changes are usually enlargements of the jaws and the front of the skull. Acromegaly can also cause thickening of the body's soft tissue structures, such as the heart, lips, and tongue. If left untreated, acromegaly can lead to serious illness and life-threatening comorbidities. Acromegaly can affect people of all ages, but it is typically diagnosed in middle-aged individuals. Rather than acromegaly, excessive growth hormone in children induces a disorder called gigantism. When excessive growth hormone starts before children's growth plates fuse or close during puberty, this condition is known as gigantism. At an annual incidence of 3–4 per million, acromegaly affects 40–60 persons per million. It is linked to higher morbidity and mortality rates, with mortality being 2–3 times higher than in a group of people of similar ages and sexes. This results from a higher risk of cancer, cardiovascular disease, and respiratory illness. Acromegaly is treated according to the specific symptoms present in each patient. The coordinated efforts of a group of professionals may be necessary throughout treatment. The goals of treatment of acromegaly are to return growth hormone levels to normal, lower the size of a pituitary adenoma (if present) to alleviate pressure on the surrounding tissue, restore optimum pituitary function, and reverse or improve related symptoms. The particular course of treatment for a given patient depends on several variables, such as the size and location of the pituitary tumor, the existence or absence of certain symptoms, the patient's age and general health, and/or other problems. Acromegaly patients may be treated with specific drugs. In cases where surgery is contraindicated, medical therapy may be advised when surgery fails to decrease large tumors before surgery or restore hormone levels to normal. Acromegaly patients are frequently treated with three major kinds of drugs. They include dopamine antagonists, growth hormone receptor antagonists, pegvisomant, and analogs of the somatostatin hormone, such as octreotide, lanreotide, and pasireotide.

[565456]

Acromegaly Market Dynamics

Rising demand is anticipated in the coming years due to the prevalence of hereditary illnesses and evolving lifestyles. The incidence of hormonal disorders, such as hypopituitarism and endocrine disorders, is expected to rise, which is projected to encourage market revenue growth. Hypopituitarism has an estimated incidence of 4.2 cases per 100,000 people per year and a prevalence of 45.5 cases per 100,000 people worldwide (without gender difference), and according to the National Organization for Rare Disorders, acromegaly occurs in approximately 50 to 70 people per million. Researchers estimate that three to eleven people from every million develop acromegaly disorder yearly. The most common cause of acromegaly is tumors on the pituitary gland. However, diabetes is another possible cause, as the disease encourages the production of growth hormones in cells. Consequently, irregularity may contribute to the aberrant stimulations that cause growth hormones to be secreted in excess. Prevalence has risen faster in low- and middle-income nations than in high-income countries. Therefore, the emergence of diabetes in the global population triggers the development of hyperpituitarism, leading to acromegaly and other diseases. Moreover, increased steroid usage can result in hormonal imbalance. Acromegaly may result from steroid usage by athletes or others. By acting on cells similarly to insulin, the high growth hormone levels brought on by steroid usage may cause them to produce more energy. According to current estimates, there are a maximum of 3 million steroid users in the United States, and 2.7%-2.9% of young American adults have used them at least once. Hence, increasing usage of steroids in daily life influences the development of acromegaly, which fuels the market growth in revenue. 

A robust pharmacological pipeline is one of the main factors influencing the acromegaly market revenue growth. For instance, FDA is anticipated to approve two growth hormone receptor antagonists and seven somatostatin analogs by 2027. A growth platform for this market is anticipated to be provided by introducing technologically enhanced detection techniques, such as radiosurgery and radiolabeled imaging technologies, that offer cost efficiency and few side effects. Furthermore, government insurance policies and programs beneficial to individuals with rare diseases are another important driver in the market's expansion. Examples include the National Institutes of Health and the National Center for Advancing Translational Sciences, which are among the numerous government healthcare agencies in the U.S. and Europe that provide subsidized medications for rare diseases. Acromegaly has been classified as an incurable disease in Japan, and insurance pays for the entire cost of care. The aforementioned activities are projected to accelerate market revenue growth in the near future.

However, the important factor limiting the growth of the market is complications related to the treatment. For instance, steatorrhea, which can be regulated, diarrhea, loose stools, malabsorption, gastrointestinal cramps, and sporadically nausea are the most common side effects of somatostatin analogs. Since somatostatin prevents gallbladder contractions, about 27% of those who took it developed gallstones.

Acromegaly Market Ecosystem

The global acromegaly market is analyzed from three perspectives: drug class, distribution channel, and region. 

Acromegaly Market by Drug Class

[86535]

Based on the drug class, the global acromegaly market is segmented into somatostatin analogs, growth hormone receptor antagonists (GHRA), dopamine agonists, and others. 

The somatostatin analogs segment accounted for the largest revenue share of the global acromegaly market in 2022. The preferred first-line medicinal therapy for treating acromegaly has been somatostatin analogs. They ought to be considered a powerful and secure treatment substitute for prolactinomas, gonadotropinomas, and corticotropinomas resistant to dopamine agonists. The first somatostatin analog to be created, octreotide, has amassed more than 30 years’ worth of evidence proving both its efficacy and safety. Pasireotide is a promising somatostatin analog now under development, and lanreotide is another somatostatin analog currently in clinical usage. There are now longer-acting depot formulations that can be administered monthly. Although octreotide was first created to manage symptoms, current findings from clinical trials show that it also has an antiproliferative impact, greatly extending the time it takes for acromegaly patients to advance. In combination with other targeted medicines, Octreotide may enhance patient results even further.

Acromegaly Market by Distribution Channel

Based on the distribution channel, the global acromegaly market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The hospital pharmacies segment accounted for the largest revenue share of the global acromegaly market in 2022. Hospital pharmacies play a key role in maximizing patient care by working with doctors, nurses, and other healthcare professionals to provide appropriate medications and supplies according to established treatment protocols. The American Society of Health-System Pharmacists surveyed hospital pharmacy practices nationally. The results show that hospital pharmacists are performing better in patient care, offering more medication-related interventions for patient transitions around the clock, confirmation of medication instructions, and medication counseling. Hospital pharmacies have a significant impact on the economics of healthcare costs. The initial course of treatment for acromegaly is transsphenoidal surgery. Aside from radiotherapy, which can result in remission after considerable time, surgery is now the only treatment that can cure the patient. As a result, those with acromegaly need to be admitted to hospitals for treatment. It also results in several concomitant conditions, such as left ventricular hypertrophy, hypertension, diabetes, and sleep apnea. Acromegaly raises the death rate when untreated (or undiagnosed). Therefore, hospitals play a major role in developing better treatment to treat multiple complications related to acromegaly. Thus, the hospital pharmacies associated with direct treatment for acromegaly show a significant revenue rise. In addition, several government initiatives, such as the subsidized drug program, help patients, regardless of their financial situation, to buy expensive treatments for rare conditions. Moreover, patients prefer hospital pharmacies due to rising drug prices and the lack of medications in retail pharmacies, resulting in a considerable revenue increase.

Acromegaly Market by Region

Based on the region, the global acromegaly market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America accounted for the largest revenue share of the global acromegaly market in 2022, due to the rising incidence of acromegaly and benevolent governmental initiatives. The expansion of key companies and their coordinated efforts to create novel formulations and guarantee high-quality products are also anticipated to increase regional segment growth. For instance, in July 2022, Ionis Pharmaceuticals, Inc. finished the phase II study to evaluate the effectiveness and safety of extended doses of IONIS GHR-LRx in patients with acromegaly as an adjunct to somatostatin receptor ligands therapy.

Acromegaly Market Competitive Landscape

The global acromegaly market is moderately competitive due to an increase in product launches, mergers, and acquisitions. Some of the primary development strategies that many organizations are prioritizing include the introduction of novel therapies, securing approval for those goods, and taking part in additional initiatives, including awareness projects. Moreover, partnerships, acquisitions, and numerous other forms of collaboration were categorized by the market players as better growth strategies. With the expanding global market demand for acromegaly, these actions have raised the chance of having profitable growth prospects in the future.

Notable participants in the global market include:

• Novartis AG
• Ipsen Pharma
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• Chiasma, Inc.
• Peptron, Inc
• WOCKHARDT
• Dauntless Pharmaceuticals
• Pfizer Inc.
• Ionis Pharmaceuticals, Inc.
• Validus Pharmaceuticals LLC

Acromegaly Market Strategic Developments

• In November 2021, ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, launched MYRELEZ (lanreotide) in Norway, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumors and symptoms associated with neuroendocrine tumors.
• In September 2021, Amolyt Pharma and PeptiDream Inc. reported that Amolyt Pharma had exercised its option to globally license a portfolio of macrocyclic peptide GHRAs under the terms of its research collaboration agreement to develop AZP-3813 as a potential treatment for acromegaly following successful research collaboration between the two companies. The identified, optimized drug candidate, AZP-3813, is being developed as a potential treatment for acromegaly for somatostatin analogs (SSAs) for patients who do not adequately respond to SSAs alone.

Frequently Asked Questions About This Report